Join SOPHiA GENETICS at Pathology Update 2025 in Australia!
We are thrilled to announce our participation in the Pathology Update 2025, organized by the Royal College of Pathologists of Australasia (RCPA), for the very first time! This prestigious event will take place in Australia, showcasing the theme: 'Excellence in Diagnosis.'
Visit us at Booth #30 to discover how SOPHiA GENETICS is revolutionising the field of precision medicine. As clinicians and pathologists work tirelessly to achieve more accurate diagnoses and improve patient outcomes, we are here to support these efforts with our innovative, data-driven solutions.
Register to Pathology Update 2025 through here
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.